Effects of Subconjunctival Bevacizumab on Corneal Neovascularization

Benayoun, Y.; Adenis, J.‐P.; Casse, G.; Forte, Raimondo; Robert, Pierre-Yves

doi:10.1097/ico.0b013e31823f8d71

Cited by 26 publications

(11 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients received up to three injections of 2.5 mg of bevacizumab (1.25 mg/0.05 mL subconjunctival and 1.25 mg/0.05 mL intrastromal). Injections were safe and well-tolerated and all patients showed a reduction in neovascularized area 61. Moreover, subconjunctival bevacizumab has been used in combination with PDT using verteporfin and showed a notable decrease in corneal neovascularization and evidence of vascular thrombosis 62.…”

Section: Indicationsmentioning

confidence: 92%

Emerging roles for antiangiogenesis factors in management of ocular disease

Saeed

Gkaragkani²,

Ali³

2013

OPTH

View full text Add to dashboard Cite

The first antivascular endothelial growth factor (anti-VEGF) was developed as an anticancer drug for colonic carcinomas. Since then, anti-VEGFs have developed in scope and indications. They have revolutionized the treatment of exudative macular degeneration and have had a major impact on treatment of several other conditions. This has resulted in an increased number of patients seeking treatment with new treatment options and has had a considerable financial impact on health care resources. Anti-VEGFs have been used in the treatment of all age groups of the population ranging from infants where it is used for treatment of retinopathy of prematurity to the elderly where it is used in exudative macular eegeneration.

show abstract

Section: Indicationsmentioning

confidence: 92%

Emerging roles for antiangiogenesis factors in management of ocular disease

Saeed

Gkaragkani²,

Ali³

2013

OPTH

View full text Add to dashboard Cite

show abstract

“…6 Herpes simpleks keratiti (HSK) de sıklıkla korneal NV oluşumuna neden olur ve batı ülkelerinde korneal körlüğün en sık enfeksiyöz kaynaklı nedenidir. 7 Sıklıkla stromal herpes simpleks enfeksiyonuna bağlı olarak korneal NV gelişmektedir. HSK tedavisinde korneal NV, hastalık seyrinde önemli olup, antianjiyojenik ajanların kullanılması gerekebilir.…”

Section: Eti̇yoloji̇ Ve Patofi̇zyoloji̇unclassified

“…HSK tedavisinde korneal NV, hastalık seyrinde önemli olup, antianjiyojenik ajanların kullanılması gerekebilir. 7 Bakteriyel kornea enfeksiyonlarında da (Staphylococcus, Streptococcus ve Pseudomonas gibi) inflamasyona bağlı olarak korneal NV sıklıkla görülmektedir. 7 Dünyada önlenebilir körlüğün önemli sebeplerinden biri konjonktivanın kronik enfeksiyonu olan trahomdur.…”

Section: Eti̇yoloji̇ Ve Patofi̇zyoloji̇unclassified

“…7 Bakteriyel kornea enfeksiyonlarında da (Staphylococcus, Streptococcus ve Pseudomonas gibi) inflamasyona bağlı olarak korneal NV sıklıkla görülmektedir. 7 Dünyada önlenebilir körlüğün önemli sebeplerinden biri konjonktivanın kronik enfeksiyonu olan trahomdur. 8 Tedavi edilmemiş trahomda kornea NV sonucu oluşan "pannus (fibrovasküler doku)" sık görülür.…”

Section: Eti̇yoloji̇ Ve Patofi̇zyoloji̇unclassified

See 1 more Smart Citation

Corneal Neovascularization and Treatment: Review

Küçükiba¹,

Yıldırım²

2017

Turkiye Klinikleri J Ophthalmol

View full text Add to dashboard Cite

“…Vascular endothelial growth factor (VEGF) is thought to be one of the key mediators in the process of NV, and the effects of anti-VEGF antibodies have been demonstrated on various experimental corneal NV models (for review see Gupta and Illingworth 2011). So far, anti-VEGF antibodies have been licensed exclusively for vitreoretinal diseases, but they are off-label for corneal NV, as there is little evidence for their efficacy on the cornea (Regenfuss et al 2009; Benayoun et al 2012). …”

Section: Introductionmentioning

confidence: 99%

Lack of association between VAP-1/SSAO activity and corneal neovascularization in a rabbit model

et al. 2013

View full text Add to dashboard Cite

The aim of this study is to determine the efficacy of a potent and specific vascular adhesive protein-1/ semicarbazide-sensitive amine oxidase (VAP-1/SSAO) inhibitor, LJP 1207, as a potential antiangiogenic and anti-inflammatory agent in the therapy of corneal neovascularization. Corneal neovascularization was induced with intrastromal suturing in rabbits (n = 20). Topical treatment with VAP-1/SSAO inhibitor LJP 1207 (n = 5, 4 times a day), bevacizumab (n = 5, daily), their combination (n = 5) and vehicle only (n = 5, 4 times a day) were applied postoperatively for 2 weeks. The development and extent of corneal neovascularization were evaluated by digital image analysis. At the end of the observation period, the level of corneal and serum VAP-1/SSAO activity was measured fluorometrically and radiochemically. The corneal VAP-1/SSAO activity was significantly elevated in the suture-challenged vehicle-treated group (3,075 ± 1,009 pmol/mg/h) as compared to unoperated controls (464.2 ± 135 pmol/mg/h, p <0.001). Treatment with LJP 1207 resulted in slower early phase neovascularization compared to vehicle-treated animals (not significant). At days 7–14, there was no significant difference in the extent of corneal neovascularization between inhibitor- and vehicle-treated corneas, even though inhibitor treatment caused a normalization of corneal VAP-1/SSAO activity (885 ± 452 pmol/mg/h). Our results demonstrate that the significant elevation of VAP-1/SSAO activity due to corneal injury can be prevented with VAP-1/SSAO inhibitor LJP 1207 treatment. However, normalization of VAP-1/ SSAO activity in this model does not prevent the development of corneal neovascularization.

show abstract

Effects of Subconjunctival Bevacizumab on Corneal Neovascularization

Abstract: Short-term results suggest that subconjunctival bevacizumab can be used safely and effectively for corneal neovascularization resulting from different ocular surface disorders, providing an additional strategy to improve success of corneal grafts.

Cited by 26 publications

References 44 publications

Emerging roles for antiangiogenesis factors in management of ocular disease

Emerging roles for antiangiogenesis factors in management of ocular disease

Corneal Neovascularization and Treatment: Review

Lack of association between VAP-1/SSAO activity and corneal neovascularization in a rabbit model

Contact Info

Product

Resources

About